Overview
Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status:
Completed
Completed
Trial end date:
2009-06-01
2009-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to determine the efficacy and safety of Rezular (arverapamil) in the treatment of IBS-D.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AGI Therapeutics, Inc.
Criteria
Inclusion Criteria:- fulfilling Rome III criteria for IBS-D
Exclusion Criteria:
- major cardiovascular disease
- psychiatric illness except mild or moderate depression
- pregnancy
- presence of other GI disease that could explain IBS-like symptoms
- history of major gastric, hepatic, pancreatic or intestinal surgery or perforation